BerandaAXGN • NASDAQ
AxoGen, Inc Common Stock
$18,18
13 Jan, 12.15.42 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
SahamSekuritas terdaftar di Amerika SerikatBerkantor pusat di Amerika Serikat
Tutup sebelumnya
$18,05
Rentang hari
$17,17 - $18,49
Rentang tahun
$5,56 - $18,49
Kapitalisasi pasar
797,43 jt USD
Volume Rata-Rata
391,56 rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD)Sep 2024Perubahan Y/Y
Pendapatan
48,64 jt17,86%
Biaya operasional
36,75 jt2,87%
Laba bersih
-1,86 jt54,56%
Margin laba bersih
-3,8261,45%
Penghasilan per saham
0,07600,00%
EBITDA
1,40 jt150,05%
Tarif pajak efektif
——
Total aset
Total liabilitas
(USD)Sep 2024Perubahan Y/Y
Investasi tunai jangka pdk
24,53 jt-24,73%
Total aset
191,98 jt-1,36%
Total liabilitas
92,58 jt-4,38%
Total ekuitas
99,41 jt—
Saham yang beredar
44,01 jt—
Harga terhadap nilai buku
7,99—
Tingkat pengembalian aset
-0,41%—
Tingkat pengembalian modal
-0,47%—
Perubahan kas bersih
(USD)Sep 2024Perubahan Y/Y
Laba bersih
-1,86 jt54,56%
Kas dari operasi
3,90 jt139,91%
Kas dari investasi
-5,00 jt-183,42%
Kas dari pembiayaan
572,00 rb11.340,00%
Perubahan kas bersih
-527,00 rb-106,91%
Arus kas bebas
3,60 jt424,35%
Tentang
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator. As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Didirikan
2002
Karyawan
427
Telusuri
Hapus penelusuran
Tutup penelusuran
Aplikasi Google
Menu utama